# OUP (Osage University Partners)

> OUP (Osage University Partners) is a VC fund backing Biotechnology. See 195 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Bala Cynwyd, United States
- Total investments: 195
- Last investment: Apr 2026
- Lead investor: 6%
- Fund size: $273M
- Last fund: Jun 2018
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/osage-university-partners/
- X (Twitter): https://twitter.com/OUP_VC
- Website: https://oup.vc/
- Facebook: https://www.facebook.com/osageuniversitypartners

OUP (Osage University Partners) is a VC fund in Bala Cynwyd focused on Biotechnology and Health Care. Osage University Partners is a venture capital firm focused on investing in startups that are commercializing university technologies. Osage partners with research universities to invest in their innovative startups shareing its investment profit with partner institutions. The firm invests in software, hardware, and life science companies at allstages of company development. To date, it has partnered with over 80 universities, including 36 of the top 50 U.S. institutions by research expenditures, and has invested in over 50 of their spinouts.

## Contacts

5 contacts available for OUP (Osage University Partners). Shizune tracks 8 team members at OUP (Osage University Partners). Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/osage-university-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 64 | 33% |
| Health Care | 49 | 25% |
| Therapeutics | 29 | 15% |
| Medical | 22 | 11% |
| Pharmaceutical | 19 | 10% |

91 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 59 | 30% |
| Series B | 42 | 22% |
| Series C | 21 | 11% |
| Funding Round | 16 | 8% |
| Series D | 10 | 5% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 105 | 54% |
| United Kingdom | 2 | 1% |
| India | 1 | 1% |
| Israel | 1 | 1% |
| Singapore | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anna Turetsky | General Partner of PxB Fund | 3 | https://shizune.co/investors/profile/anna-turetsky |
| Beth Grafstrom | Vice President of Finance | 0 | https://shizune.co/investors/profile/beth-grafstrom |
| Kirsten Leute | Partner, University Relations | 0 | https://shizune.co/investors/profile/kirsten-leute |
| Louis Berneman | Founding Partner | 0 | https://shizune.co/investors/profile/louis-berneman |
| Marc Singer | Managing Partner | 27 | https://shizune.co/investors/profile/marc-singer |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Terremoto Biosciences | Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. | $108M | Series C | Apr 15, 2026 |  |
| Precede Biosciences | Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $63.5M | Series B | Jan 12, 2026 |  |
| Nocion Therapeutics | Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation. | $23M | Series B | Jan 07, 2026 |  |
| Addition Therapeutics | Addition Therapeutics focuses on developing RNA-only therapeutics using its proprietary PRINT technology. This approach enables the precise insertion of genetic elements at specific safe harbor sites, aiming to transform the field of genetic medicine. They operate within the biotechnology industry and are backed by venture capital. Their innovativemethods target gene editing and regulation, potentially offering new solutions in the field of genetic therapies. | $100M | Series A | Dec 17, 2025 |  |
| RapidFire AI | RapidFire AI provides an agile deep learning development platform to accelerate AI development while reducing infrastructure costs | $4M | Pre-Seed | Sep 23, 2025 |  |
| Neuros Medical | Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine. | $56M | Series D | Jul 09, 2025 |  |
| University of Puerto Rico-Bayamon | University of Puerto Rico-Bayamon | $2.3M | Grant | Jun 17, 2025 |  |
| AssetWatch | AssetWatch is a leader in proactive and predictive maintenance solutions, providing a rapidly deployable, end-to-end remote condition monitoring service. We help eliminate unplanned downtime for global manufacturers and simplify the predictive maintenance process by providing a network of wireless sensors and communication hubs, cutting-edgesoftware, and condition monitoring engineers who condense and decipher the noise of data – making it more qualitative than just quantitative with expert prescriptive recommendations. By combining predictive analytics via machine learning in the software with the prescriptive insights of a certified expert, AssetWatch gives you way more than just the standard "pass/fail". We truly are a partner in the journey, helping change the culture of maintenance and reliability teams from reactive to proactive. | $75M | Series C | Apr 30, 2025 |  |
| Virtue AI | Virtue AI operates as an AI security and compliance platform for applications. | $30M | Series A | Apr 15, 2025 |  |
| Virtue AI | Virtue AI operates as an AI security and compliance platform for applications. |  | Seed | Apr 15, 2025 |  |

10 of 195 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 28 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 14 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 14 deals together
- [U.S. Venture Partners](https://shizune.co/investors/profile/us-venture-partners) — VC Fund, 14 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 13 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 12 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does OUP (Osage University Partners) invest in?

OUP (Osage University Partners) invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 195 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact OUP (Osage University Partners)?

Public channels for OUP (Osage University Partners) include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at OUP (Osage University Partners)?

The team at OUP (Osage University Partners) includes Anna Turetsky (General Partner of PxB Fund), Beth Grafstrom (Vice President of Finance) and Kirsten Leute (Partner, University Relations), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co